Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...

The Medscape team is back in Chicago for the much-anticipated ACC 2025 conference,  March 29-31, bringing an array of ...

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

and when left ventricular (LV) hypertrophy exists, they do not regress LV mass as well as diuretics. In addition, there were BP differences between the two treatment limbs favoring the ...

Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...

HOLDINGS has completed a draw on its Equity Line of Credit to support the commercial launch of Arbli Oral Suspension, while ...

for the reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and for the treatment of diabetic nephropathy with an elevated serum creatinine and ...

(Ultra)Endurance exercise and cardiac function In summary, there is now convincing evidence that the performance of (ultra)endurance exercise can result in a small but temporary reduction in LV and RV ...

Influence of depression trajectories in heart failure patients with preserved ejection fractions: a secondary analysis of adverse outcomes in the TOPCAT trial ...

Background Mechanical stress on the heart is commonly considered the sole stimulus explaining the synthesis and release of ...